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A B S T R A C T
The additional effect of omega-3 supplementation in association with lifestyle modifica-
tion program (LSMP) in free living-adults was evaluated.We studied 39 adults (control group
with LSMP (G1, n = 16) and LSMP plus supplementation of 3 g of fish oil per day (360 mg of
docosahexaenoic acid and 540 mg of eicosapentaenoic acid) (G2, n = 23)) during 20 weeks.
The fish oil group showed a significant decrease in waist circumference (1.3%) followed by
metabolic syndrome reduction (29%) mainly due to normalization of blood pressure (33.3%)
and triacylglycerol (27.3%). Omega-3 supplementation provided additional benefits to LSMP
in the resolution of metabolic syndrome.
© 2015 Elsevier Ltd. All rights reserved.
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1. Introduction
The metabolic syndrome (MS) has usually been defined as a
clustering of numerous factors that increase cardiovascular risk
(Takahashi et al., 2011), such as dyslipidemia,abdominal obesity,
hypertension, and high fasting glycemia, which increases
prothrombotic and proinflammatory markers (Grundy, 2006;
Orsatti et al., 2012). MS prevalence has increased significantly
over the last years, reaching pandemic proportions worldwide
(Ford, Giles, & Mokdad, 2004) and the etiology includes several
genetic,metabolic and environmental factors (Mirmiran, Noori,
& Azizi, 2008). Among environmental factors, diet and exer-
cise are the main factors related to the increase in MS rates
(Buckland, Salas-Salvado, Roure, Bullo, & Serra-Majem, 2008).
Recently our research group has shown that MS is related to
a higher intake of saturated fat and low diet variety and fruit
intake (de Oliveira, McLellan, Vaz de Arruda Silveira, & Burini,
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2012). Additionally, some studies have shown that dietary
changes, including diets low in refined carbohydrates and fats
and high in fiber, such as the Mediterranean diet, can reduce
the risk of MS (Babio et al., 2009; Mecca et al., 2012).
Another dietary intervention that seems to reduce the preva-
lence of MS is a high intake of omega-3 fatty acids (Poudyal,
Panchal, Diwan, & Brown, 2011). The protective effect of these
fatty acids is mainly due to linolenic acid, eicosapentaenoic
acid (EPA), and docosahexaenoic acid (DHA) (Campioli,
Rustichelli, & Avallone, 2012; Poudyal et al., 2011). The typical
Western diet is a risk factor for MS (Lutsey, Steffen, & Stevens,
2008) and one of the factors is the omega-6 to omega-3 ratio,
which is very high when compared to earlier diets (Poudyal
et al., 2011).This ratio is approximately 10:1 (Connor, 2000) and
this occurs due to dietary changes, especially an increased
intake of oils, especially soybean, corn, sunflower, safflower,
and cotton seed oils, which are rich in omega-6 (Russo, 2009).
The omega-3 supplementation has an effect on reducing
the omega-6 to omega-3 ratio and increasing resolvin and
protectin thathas important anti-inflammatory effects (Goldberg
& Katz, 2007) and also can reduce the risk factors for MS, with
significant effects in all MS components (Poudyal et al., 2011;
Stanley et al., 2007).Wehave already shown that lifestyle change
and physical exercise associated with a proper diet can reduce
the prevalence of MS by 24% (Mecca et al., 2012) but the ad-
ditional effect of omega-3 supplementationwasnot yet observed.
Therefore, the objective of this studywas to investigate the ad-
ditional benefit of omega-3 supplementation in associationwith
lifestyle modification program (LSMP) on the resolution of the
MS and its components in overweight adults.
2. Methods
2.1. Subjects
This is a clinical, prospective study with 39 adults aged 36 to
64 years, 33 females and 6 males, clinically selected for the
LSMP from August 2009 to July 2010. Initially, 123 adults were
assessed. Of these, 64 did not start the program and 20 did not
complete the 20-week intervention protocol.The LSMP offered
to patients with chronic non-communicable diseases in
Botucatu city (São Paulo, Brazil) consists of supervised exer-
cise and nutritional counseling (Mecca et al., 2012).The studied
subjects were part of a subgroup (convenience sample) of par-
ticipants clinically screened for the lifestyle change program
“Mexa-se Pró-Saúde” [Exercise for Health]. All individuals signed
an informed-consent form, which, conjointly with the project,
was approved by the Research Ethics Committee (document
no. OF. 364/2009 – CEP) of the Botucatu School of Medicine (FMB
– UNESP).The anthropometric, biochemical, dietary, and physi-
cal assessments were done at baseline and after 20 weeks of
intervention (after LSMP).
3. Study design
3.1. Nutritional intervention
The participants were divided into two groups. The control
group with LSMP, n = 16; and another group receiving omega-3
PUFA supplementation and LSMP, n = 23. The omega-3 PUFA
was instructed to take 3 capsules (1 g each) of fish oil daily
(Naturalis®). Each capsule contained 120 mg of DHA and 180 mg
of EPA.The participants of the supplemented group were asked
to consume the capsules together with themainmeals (2 during
lunch and 1 during supper).The opportunity to join the omega-3
PUFA group was given to all participants and adherence was
spontaneous. The study lasted 20 weeks.
3.2. Exercise intervention
All participants were submitted to supervised exercise of 80
minutes, including warm up (20 min) walking (40 min)/stretch-
ing (20 min), 3 times/week complemented with 60 min (2 times/
week) of resistance training (40 min), and stretching (10 min)
at a gym. Only participants with a minimum attendance of 3
times/week were included in the study.
3.3. Body composition
Body weight was measured by a platform-type anthropomet-
ric scale (Filizola®) with a maximum capacity of 150 kg and
an accuracy of 0.1 kg. Height was measured by a portable Seca®
stadiometer with accuracy of 0.1 cm (Heyward & Stolarczyk,
2000). The body mass index (BMI) was calculated by dividing
the body weight by the square of the height.
Waist circumference (WC) was measured at the midpoint
between the last rib and the iliac crest. A steel Sanny® an-
thropometric tape measure (without a lock) was used for all
measurements.
A bioelectrical impedance device (Biodynamics®,model 450,
Seattle, WA, USA) was used to determine percentage of body
fat (% body fat) (Segal, Van Loan, Fitzgerald, Hodgdon, & Van
Itallie, 1988).
3.4. Dietary intake
Dietary intake was assessed using a single 24-hour dietary recall
at baseline and M1. The diet was documented by trained pro-
fessionals, and in order to obtain accurate information, the
subjects were asked how often they usually ate during the day,
what foods were consumed, how the food was prepared, what
the serving size was, and what food/meal brands were con-
sumed. The diets were analyzed by NutWin® software (2002),
version 1.5 (NutWin, 2002), and the main nutrients of inter-
est were energy, protein, fat (saturated, monounsaturated and
polyunsaturated), cholesterol, carbohydrates, and fiber. Mean
individual nutrient intakes per day were computed using the
NutWin database and Brazilian food tables (IBGE, 1999;
NEPA/UNICAMP, 2004; Philippi, 2002).The Healthy Eating Index
(HEI) modified for the Brazilian population was used to assess
diet quality (Mota et al., 2008). The original HEI was based on
a 10-component system of five food groups with a total pos-
sible index score of 100. This method was adapted for the
Brazilian population based on the Brazilian food guide, which
has eight food groups and 12 components to measure diet
variety. Each of the 12 components has a score ranging from
0 to 10; therefore the total possible index score is 120.
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3.5. Cardiorespiratory fitness
Cardiorespiratory fitness was determined by maximum oxygen
consumption (VO2max) using an electric treadmill (model
QMCTM90) according to the Balke protocol (Balke &Ware, 1959).
The respiratory indices were continually measured by an open
circuit ergospirometric system (model QMCTM90Metabolic Cart,
Quinton®, Bothell, WA, USA) with the mix-chamber method
and with constant monitoring of the heart and respiratory rates
and blood pressure.
3.6. Blood pressure
Systolic (SBP) and diastolic (DBP) blood pressure (BP) was evalu-
ated with the individual in the seated position according to
the procedures described by the VI Brazilian Guidelines on
Arterial Hypertension (Sociedade Brasileira de Cardiologia, &
Sociedade Brasileira de Hipertensão, 2010), using properly sized
cuffs for arm circumference, considering the width/length
proportion of 1:2, and the width of the cuff’s rubber bag, which
should correspond to 40% of arm circumference, and length,
to at least 80%.
3.7. Biochemical analyses
Blood sampleswere collected by vacuumvenous puncture, after
a 10 to 12-h fasting period, and centrifuged to obtain serum
and plasma samples which were stored at −80 °C until the end
of the study. The individuals were previously advised to not
performvigorousphysical exercises 24 hand/or consumealcohol
72 h prior to blood collection. Plasma triacylglycerol, total
cholesterol (Total-c), high-density lipoprotein cholesterol
(HDL-c), uric acid (UA), creatinine (Cr), and gamma-glutamyl
transpeptidase (gGT) were assayed by dry-chemistry (Systems
Vitros chemistry 950 Xr). Plasma low-density lipoprotein cho-
lesterol (LDL-c) was calculated using the Friedewald equation
(Friedewald, Levy, & Fredrickson, 1972),malondialdehyde (MDA)
was assayed by high-performance liquid chromatography and
high-sensitivity C-reactive protein (hS-CRP) by chemilumines-
cence (Immulite, 2000).
3.8. Metabolic syndrome
Diagnosis of the MS was performed according to the NCEP-
ATP III criteria (Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults, 2001) with ad-
aptation for glucose values (American Diabetes Association,
2004). The 5 components used were hypertension, abnormal
WC, high plasma levels of triglycerides and glucose, and low
levels of HDL-c.The metabolic syndrome was diagnosed when
3 or more of these components were abnormal.
3.9. Statistical analysis
The data were analyzed by the software SAS version 9.2 for
Windows. Descriptive statistics were performed for the study
and continuous variables, presented as means ± standard de-
viation. Categorical variables were presented as percentages.
Samples were tested for normal distribution (Shapiro–Wilk) and
groups were compared by either the ANOVA two-way or
Kruskal–Wallis test. The chi-square test compared the differ-
ences between the prevalence of metabolic syndrome
components. The results were discussed based on a signifi-
cance level of 5% (p < 0.05).
4. Results
At baseline, groups had different energy intakes but at the end
of the study the energy intake was similar between the groups.
Macronutrient and fiber intake at baseline and end of the study
did not vary between the groups, except for polyunsaturated
Table 1 – Dietary intake of control group and omega-3 PUFA group at baseline and after LSMP.
Control group W-3 PUFA group
Baseline After LSMP Baseline After LSMP
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Total calories (kcal) 1051 ± 371aA 1214 ± 336a 1535 ± 645aB 1454 ± 445a
Carbohydrates (g/kg) 2.3 ± 0.8a 2.6 ± 0.9a 2.78 ± 0.96a 2.6 ± 0.92a
Carbohydrates (%) 56.5 ± 11.6a 56.3 ± 8.7a 56.2 ± 8.3a 52.8 ± 9.4a
Proteins (g/kg) 0.6 ± 0.3a 0.8 ± 0.4a 0.79 ± 0.31a 0.81 ± 0.35a
Proteins (%) 15.4 ± 5.2a 16.2 ± 5.1a 16.2 ± 5.2a 17.3 ± 6.3a
Total lipids (g/kg) 0.48 ± 0.3a 0.63 ± 0.32a 0.61 ± 0.24a 0.65 ± 0.33a
Total lipids (%) 28 ± 8.9a 29.2 ± 6.8a 27.6 ± 6.4a 29.3 ± 7.7a
Monounsaturated lipids (g) 10.2 ± 8.4a 13.2 ± 6.5a 14.9 ± 7.1a 13.2 ± 6.3a
Monounsaturated lipids (%) 8.2 ± 3.8a 9.4 ± 3a 8.7 ± 2.9a 8.2 ± 2.8a
Polyunsaturated lipids (g) 7.4 ± 5.9a 12.1 ± 5.3a 9.8 ± 6.7a 14.4 ± 6.4b
Polyunsaturated lipids (%) 5.9 ± 3a 8.7 ± 2.6a 5.8 ± 2.7a 9.2 ± 3.5b
Saturated lipids (g) 10.9 ± 7.7a 11.2 ± 6.6a 16.1 ± 9.1a 14.8 ± 8a
Saturated lipids (%) 8.8 ± 4a 8 ± 2.8a 9.3 ± 3.4a 9 ± 3.4a
Fiber (g) 12.5 ± 5.7a 15.4 ± 7.3a 12.4 ± 8.5a 14.2 ± 7.2a
LSMP: Lifestyle modification program.
Values were significant when p < 0.05.We considered a > b > c. A and B are different at basal moment.Weight = adjusted for sex and age; BMI = sex,
age, and total caloric intake; other variables adjusted for sex, age, BMI, and total caloric intake.
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fatty acid intake, which was higher in the group receiving
omega-3 supplementation (Table 1).
Body weight, BMI, and % of body fat did not change in either
group with the intervention. Cardiorespiratory fitness behaved
similarly in both groups, with an increase in VO2max and time
on treadmill by the end of the study, showing the benefit of
exercise in both groups. Furthermore, malondialdehyde of
control group (oxidative stress) increased, while omega-3 did
not change. No changes were detected for other variables
(Table 2).
Regarding the MS components, HDL-c increased signifi-
cantly in both groups, showing the benefits of a lifestyle
modification program intervention regardless of omega-3 PUFA
supplementation. We observed additional effects of omega-3
supplementation in omega-3 PUFA group. Systolic and dia-
stolic blood pressures andWC values reduced after LSMP with
omega-3 supplementation. In control group we did not observe
these differences (Table 3).
When analyzing changes in the prevalence of MS and its
components, we observed a significant decrease in MS preva-
lence in the omega-3 PUFA group (from 48 to 19%). Furthermore,
we observed a significant decrease in the prevalence of hy-
pertension (SBP from 43 to 10% and DBP from 33 to 10%) and
high triacylglycerol (from 50 to 23%) in the omega-3 PUFA group
(Table 3).
5. Discussion
The main finding of the present study was that LSMP in ad-
dition with supplementation of 3 g of fish oil during 20 weeks
Table 2 – Anthropometric, clinical and blood markers in control group and omega-3 PUFA group at baseline and after
LSMP.
Control group W-3 PUFA group
Baseline After LSMP Baseline After LSMP
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Weight (kg) 69.2 ± 14a 68.4 ± 14.9a 78.0 ± 18.9a 76.9 ± 18.3a
BMI (kg/m2) 28.4 ± 5.8a 28 ± 6a 30.3 ± 5.7a 29.9 ± 5.5a
% of body fat 34 ± 7.8a 33. ± 7.1a 36 ± 9a 34.7 ± 8.1a
Hip circumference (cm) 101 ± 8.9a 102 ± 10.5a 106 ± 11.2a 105 ± 11.6a
Cholesterol (mg/dL) 193 ± 27a 201 ± 35a 208 ± 47.5a 214 ± 43.4a
LDL-cholesterol (mg/dL) 115 ± 17.6a 120 ± 29.4a 130 ± 42.2a 133 ± 35.3a
Uric acid (mg/dL) 4.4 ± 1.2a 4.5 ± 0.9a 4.7 ± 1.4a 4.8 ± 1.5a
Insulin 15.9 ± 11.9a 12.9 ± 11.9a 13 ± 7.8a 13.4 ± 7.1a
QUICK 0.32 ± 0.03a 0.34 ± 0.04a 0.33 ± 0.03a 0.33 ± 0.03a
HOMA – B 179 ± 144a 153 ± 138a 195 ± 223a 252 ± 240a
MDA (µmol/L) 0.87 ± 0.2a 1.2 ± 0.3b 1 ± 0.5a 1.1 ± 0.2a
CRP (mg/dL) 0.38 ± 0.37a 0.6 ± 0.8a 0.34 ± 0.32a 0.35 ± 0.3a
HOMA – IR 4.3 ± 4.3a 4.1 ± 5.6a 3.3 ± 2.1a 3.3 ± 2.4a
Dynamometry(kg) 31 ± 9a 31 ± 5.4a 33.8 ± 14.6a 31.35 ± 7.4a
VO2 (mL·kg·min−1) 29.8 ± 6.5a 37.75 ± 5b 31 ± 5.7a 33.67 ± 4.7b
Treadmill time (seconds) 535 ± 207a 656 ± 182b 597 ± 168a 680 ± 140b
LSMP: Lifestyle modification program; BMI = body mass index; MDA = malondialdehyde; CRP = C-reactive protein; HOMA-IR = insulin resis-
tance index; VO2max = maximum oxygen consumption. Significant values were p < 0.05. We considered b different from a. Weight = adjusted
for sex and age; BMI = sex, age, and total caloric intake; WC adjusted for sex, age; other variables adjusted for sex, age, BMI, and total caloric
intake.
Table 3 – Metabolic syndrome components and its percentage of alteration in control group and omega-3 PUFA group at
baseline and after LSMP.
Control group W-3 PUFA group
Baseline After LSMP Baseline After LSMP
Mean ± SD % of
alteration
Mean ± SD % of
alteration
Mean ± SD % of
alteration
Mean ± SD % of
alteration
Metabolic syndrome – 38a – 50a – 48a – 19b
Waist circumference (cm) 90.3 ± 12.1a 50a 88.5 ± 11.4a 50a 92 ± 12.2a 41a 90.8 ± 12b 45a
SBP (mmHg) 121.6 ± 19a 21a 121.6 ± 15a 30a 125.6 ± 15.3a 43a 112.7 ± 12b 10b
DBP (mmHg) 78.5 ± 12a 29a 75.3 ± 10a 15a 81 ± 11a 33a 72.5 ± 8.5b 10b
HDL-cholesterol (mg/dL) 44 ± 11.1a 77a 51.2 ± 12.7b 46a 44.6 ± 11.2a 73a 50.9 ± 11.8b 54a
Triacylglycerol (mg/dL) 170 ± 66.3a 53a 147 ± 78.6a 38a 166 ± 67.8a 50a 150 ± 82.3a 23b
Glycemia (mg/dL) 102 ± 29a 31a 105 ± 30.1a 34a 102 ± 34.8a 32a 94.1 ± 31.7a 23a
LSMP: Lifestyle modification program; SBP = systolic blood pressure; DBP = diastolic blood pressure. Significant values were p < 0.05. We con-
sidered b different from a.
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showed a decrease in systolic and diastolic blood pressure and
waist circumference values and decreased the prevalence of
high triacylglycerol, probably reflecting on resolution of MS,
which did not occur in the control group. Interestingly, some
variables decreased in values and others when analyzing the
prevalence of alteration. It can be explained because some in-
dividuals presented somevariables values toomuchhigher than
cut-off point and results in reduction of mean values, but not
in classification. The contrary was also observed; TG did not
decrease mean values, but diminished the prevalence of al-
teration becauseTG values were near the normal cut-off value.
The proper intake is 3 to 3.5 g of fish oil per day (Carpentier,
Portois, & Malaisse, 2006), which corresponds to the study
dosage (Carpentier et al., 2006). Some studies have shown that
omega-3 can prevent weight gain (Buckley & Howe, 2010; Krebs
et al., 2006; Ryan & Seeley, 2013). Omega-3 seems to reduce the
activity of some nuclear receptors, among them peroxisome
proliferator-activated receptor γ (PPAR γ). This nuclear recep-
tor regulates the transcription of important genes for lipid
metabolism. High PPAR γ activity increases the lipid reserves
in the adipose tissue and acts on the brain causing hyperpha-
gia, both factors related to an increase in body fat (Lu et al.,
2011; Ryan et al., 2011). Based on these factors, low PPAR γ ac-
tivity causes less storage of fat in the adipose tissue and brain,
reducing the stimulus to consume high-fat diets (Lu et al., 2011;
Ryan et al., 2011; Ryan & Seeley, 2013).
The SBP and DBP decreased in omega-3 PUFA group after
20 weeks whereas blood pressure of control group did not
change. Many clinical trials and meta-analyses have found that
supplements with high omega-3 dosages can lower blood
pressure in hypertensives (Appel, Miller, Seidler, & Whelton,
1993; Morris, Sacks, & Rosner, 1993). Supplementation with
1.9 g/day of omega 3 PUFA improved vasodilator function
(Hill, Buckley, Murphy, & Howe, 2007) and results can be con-
firmed in twometa-analyses of controlled studies, whereas 3 g/
day and 6 g/day of omega-3 resulted in a decrease of 4/3 mmHg
in hypertensive individuals (Appel et al., 1993; Morris et al.,
1993). The probable mechanism for blood pressure reduction
after omega-3 intake could be the antagonistic effect of
angiotensin receptors (Poudyal et al., 2011).
Although triacylglycerol did not decrease quantitatively, high
triacylglycerol prevalence decreased significantly. Other studies
have shown similar effects of omega-3 supplementation on
dyslipidemia parameters (Kelley, Siegel, Vemuri, & Mackey, 2007;
Khandelwal et al., 2013; Munro & Garg, 2011). Kelley et al. (2007)
found a reduction of triacylglycerol in men aged 39 to 66 years
with high triacylglycerol after 45 days of taking 3 g of fish oil
per day. Another study found that the prevalence of high
triacylglycerol decreased by 27% in individuals taking 6 g/day
of fish oil (n = 17) (Munro & Garg, 2011), similar to the present
study.
Some theories have been proposed to explain how omega-3
reduces triacylglycerol. The strongest evidence is the reduc-
tion in hepatic lipogenesis, reducing hepatic secretion of VLDL
(Jacobson, 2008). Furthermore, omega-3 inhibits certain enzymes
involved in the hepatic synthesis of triacylglycerol, reducing
its plasma level (Agerholm-Larsen, Nordestgaard, Steffensen,
Jensen, & Tybjaerg-Hansen, 2000).
HDL-c increased in both groups, possibly because of physi-
cal activity, since the groups did not differ otherwise. Other
studies have already reported that physical activity increases
HDL-c (Couillard et al., 2001; Kraus et al., 2002), and that in-
dividuals submitted to aerobic training showed a reduction in
total cholesterol and an increase inHDL-c (Kelley, Kelley, & Tran,
2004). Data regarding HDL-c are still divergent. While some
studies found that HDL-c increased (Kesavulu, Kameswararao,
Apparao, Kumar, & Harinarayan, 2002; Pedersen et al., 2003),
others have found that omega-3 did not change it (Luo et al.,
1998; Moore et al., 2006). More studies are necessary to deter-
mine the effect of omega-3 onHDL-c. LDL-c also did not change
with the intervention in either group. Some studies did not find
changes in total cholesterol or LDL-c (Kesavulu et al., 2002;
Petersen, Pedersen,Major-Pedersen, Jensen,&Marckmann, 2002).
One of the most interesting result of this study was the reso-
lution of MS by 29% due to omega-3 supplementation, which
corroborated with another study and reinforces the impor-
tance of this oil in MS prevention and treatment (Baik, Abbott,
Curb, & Shin, 2010). The prevalence of nearly all MS compo-
nents decreased (waist circumference, high blood pressure,
high triacylglycerol, and increase in HDL-c), which has already
beenmentioned and justifies the resolution of MS in this group.
Furthermore, this study provides new insights regarding
the interaction between exercise and diet in the MS resolu-
tion once we observed additional effects of omega-3 PUFA in
a LSMP.
The only component that was not affected by supplemen-
tation in the present study was plasma glucose. However,
another study found that omega-3 supplementation reduced
glycemia and improved insulin resistance (Ebbesson, Risica,
Ebbesson, Kennish, & Tejero, 2005). Our population pre-
sented values related to glucose intolerance, so the values were
not high and the subjects would probably not benefit from
supplementation.
Although physical activity (measured by VO2max and tread-
mill time) and physical fitness (measured by dynamometry)
improved in both groups after 20 weeks, these variables did
not differ significantly between the groups, indicating the benefit
of the lifestyle modification program regardless of supplemen-
tation. It has been shown that a strong relationship between
physical inactivity and the presence of cardiovascular risk
factors, such as high blood pressure, insulin resistance,
diabetes, dyslipidemia, and obesity and that regular physical
activity is important to prevent MS (Rennie, McCarthy,
Yazdgerdi, Marmot, & Brunner, 2003), however the exercise
without omega-3 was not efficient to reduce MS in our
study.
While malondialdehyde of controls increased after 20
weeks, omega-3 supplementation did not change. The litera-
ture has shown that omega-3 can lower C-reactive protein and
malondialdehyde concentrations (Kremer, 2000), but the present
study found no reduction in C-reactive protein, probably because
of the low basal concentration of this parameter.
A strong point of our study was the correct control of
diet and exercise. Both groups did not change the intake of
macronutrients and the only intervention and change was poly-
unsaturated fat intake because of omega-3 supplementation.
Furthermore, all individuals realized the same protocol of
exercise, which show that difference between groups oc-
curred only because of additional intervention with omega-3
supplementation.
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6. Study limitations
The study population consisted of a convenience sample where
the participants chose to participate in the lifestyle change
program. This study was realized with individuals joining a
lifestyle modification program (healthy diet and exercise),
so these results cannot be extrapolated to other populations
(sedentary individuals). Also, an important limitation of this
study was the absence of measuring fatty acid concentra-
tions in the bloodstream.
7. Conclusion
We concluded that omega-3 PUFA supplementation during 20
weeks provides additional benefits to a lifestyle modification
program protocol in the resolution of MS by reducing blood pres-
sure, waist circumference and high triacylglycerol prevalence.
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